Nanochon Announces Health Canada Approval for First in Human Investigation
WASHINGTON–(BUSINESS WIRE)–Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial.
The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada. Dr. Fathi Abuzgaya is an orthopedic surgeon by training and an esteemed researcher with a track record over the last 25 years, leading +600 clinical trials in all phases and therapeutic areas.
